Physician profile
Amardeep S Mann
NPI 1396715181
$20,609.88
in general payments reported to CMS, 2019-2025
29 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $4,587 · 2021: $3,432 · 2022: $5,763 · 2023: $2,776 · 2024: $742 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,105 · Food and Beverage: $2,003 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,105.20 |
| Food and Beverage | $2,002.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13,502.10 | 2019-2023 | Lifevest |
| Abbott Laboratories | $4,693.99 | 2019-2025 | Aveir, Jot Dx, Assurity |
| Medtronic, INC. | $840.98 | 2022-2024 | Venaseal, Linq II, Azure Xt Dr Mri Surescan |
| Pfizer INC. | $269.34 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $218.02 | 2024-2025 | Entyvio |
| Amgen INC. | $156.21 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.87 | 2023-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $92.18 | 2023-2025 | Lokelma, Farxiga |
| Kowa Pharmaceuticals America, INC. | $70.31 | 2019 | |
| W. L. Gore & Associates, INC. | $52.92 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $50.28 | 2022-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $48.71 | 2022-2024 | Capvaxive |
| Novartis Pharmaceuticals Corporation | $47.82 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.84 | 2024-2025 | Xifaxan |
| Braintree Laboratories, INC. | $39.97 | 2023-2024 | Suflave, Sutab |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36.89 | 2023-2025 | Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $36.14 | 2022 | |
| United Therapeutics Corporation | $31.12 | 2024 | Orenitram |
| Boston Scientific Corporation | $28.62 | 2025 | Cds Broad Portfolio Offering |
| Otsuka America Pharmaceutical, INC. | $28.16 | 2024 | Rexulti |
| Irhythm Technologies, INC. | $27.43 | 2024 | Zio Xt Patch, Zio Monitor |
| Madrigal Pharmaceuticals | $26.39 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $25.86 | 2025 | |
| Celltrion USA INC. | $21.96 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $21.93 | 2024 | Oxlumo |
| Qol Medical, LLC | $19.56 | 2023 | Sucraid |
| Innovation Technologies INC | $17.33 | 2023 | Irrisept |
| Echosens North America, INC. | $14.51 | 2025 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $14.44 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amardeep Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.